Customize your JAMA Network experience by selecting one or more topics from the list below.
Physicians and patients in search of outpatient monoclonal antibody therapies for coronavirus disease 2019 (COVID-19) can turn to a recently launched federal government website and enter their zip code.
In November, the Food and Drug Administration authorized emergency use of the monoclonal antibodies for treating patients with mild or moderate COVID-19 who are at high risk of developing more severe disease that requires hospitalization. Clinical trial data as well as anecdotal information from communities suggest that the monoclonal antibodies might prevent the worsening of symptoms and keep patients out of the hospital.
The US Department of Health and Human Services has signed agreements with Regeneron to buy about 300 000 courses of its casirivimab and imdevimab combination treatment and with Eli Lilly and Company to buy about 3 million courses of its bamlanivimab therapy if needed.
Only facilities that are open to the public are listed, so the locator does not include facilities that treat specific groups, such as patients in long-term care, skilled nursing, or psychiatric facilities or prisons.
Rubin R. Locating COVID-19 Monoclonal Antibody Therapies. JAMA. 2021;325(8):712. doi:10.1001/jama.2021.1230
Coronavirus Resource Center
Create a personal account or sign in to: